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Abstract
Background & Aims—Eosinophilic esophagitis (EoE) is of increasing prevalence and thought
to result from allergic processes. Helicobacter pylori has been inversely associated with allergic
diseases, but there is no known relationship between H. pylori, EoE and esophageal eosinophilia.
We investigated the association between esophageal eosinophilia and H. pylori infection.
Methods—We performed a cross-sectional study of data, collected from a United States
pathology database, on 165,017 patients in the US who received esophageal and gastric biopsies
from 2008 and 2010. Patients with and without H. pylori on gastric biopsy were compared and
odds of esophageal eosinophilia were determined.
Results—From the data analyzed, 56,301 (34.1%) had normal esophageal biopsies, 5,767 (3.5%)
had esophageal eosinophilia, and 11,170 (4.8%) had H. pylori infection. Esophageal eosinophilia
was inversely associated with H. pylori (odds ration [OR]: 0.77, 95% confidence interval [CI]:
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0.69–0.87). Compared to patients with normal esophageal biopsies, odds of H. pylori were
reduced among patients with ≥15 eosinophils per high-power field (eos/hpf) (OR 0.79; 95% CI
0.70–0.88), ≥45 eos/hpf (OR 0.75; 0.61–0.93), ≥75 eos/hpf (OR 0.72; 0.62–0.83), and ≥90 eos/
hpf (OR 0.52; 0.31–0.87) (p for trend <0.001). A similar dose-response trend was observed for
increasing clinical suspicion for EoE and decreasing prevalence of H pylori. Additionally, severity
of histologic effects of H. pylori was inversely associated with esophageal eosinophilia. All trends
held in multivariate analysis.
Conclusions—In a large cross-sectional analysis, H. pylori infection was inversely associated
with esophageal eosinophilia. This relationship could have implications for the pathogenesis and
epidemiology of EoE.
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Introduction
Eosinophilic esophagitis (EoE) is a chronic disease of the esophagus characterized by
dysphagia and dense esophageal eosinophilia in the absence of gastroesophageal reflux
disease (GERD).1 First described in 1978 and initially felt to be rare,2, 3 the incidence and
prevalence of EoE have rapidly increased over the past decade.4–8 Currently, between 5–
15% of patients undergoing endoscopic evaluation for dysphagia will have EoE,9–11 and
greater than 50% of patients presenting to an emergency room with food impaction are now
diagnosed with EoE.12, 13 The pathogenesis of EoE is believed to be an immune-mediated
allergic process,14 but the etiology is unknown.
Given the dramatic epidemiologic shift regarding EoE, environmental exposures have been
postulated to play a role.15 One early life exposure, Helicobacter pylori, has been inversely
associated with conditions such as asthma, allergic rhinitis and atopic dermatitis, and
biologic plausibility for a protective role of H. pylori in allergic disease is emerging.16–19
While there is an ecologic association between the decreasing prevalence of H. pylori and
the increase in EoE, the association between H. pylori infection, EoE, and esophageal
eosinophilia is poorly understood.
The primary objective of this study was to determine the association between esophageal
eosinophilia and H. pylori in a large set of gastric and esophageal biopsy specimens. We
hypothesized that the presence of H. pylori would be inversely associated with increasing
esophageal eosinophilia. The secondary objectives were to determine the association
between patients suspected of having EoE and H. pylori, and between esophageal
eosinophilia and different H. pylori disease manifestations in the stomach. We hypothesized
that the presence of H. pylori would be inversely associated with increasing clinical
suspicion for EoE, and that esophageal eosinophilia would be inversely associated with
more severe manifestations of H. pylori.
Methods
Study Design and Data Source
This is a cross-sectional study of all patients with esophageal biopsies examined between
January 1, 2008 and November 26, 2010 by pathologists at Caris Life Sciences. The Caris
Institutional Review Board and the University of North Carolina Institutional Review Board
approved the study.
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Caris Life Sciences is a specialized pathology laboratory serving outpatient endoscopy
centers throughout the United States. They review samples from 43 states, Washington D.C.,
and Puerto Rico, with central specimen processing in one of three labs (Irving, Texas;
Phoenix, Arizona; Boston, Massachusetts). Each laboratory follows identical sectioning and
staining procedures. An experienced group of sub-specialty trained gastrointestinal
pathologists originally reviewed the slides for clinical purposes. Biopsy interpretation is
performed using a standardized protocol with uniform diagnostic criteria. All biopsy reports
are deposited into a central database, which also includes information about patient age, sex,
and indication for esophagogastroduodenoscopy (EGD). For the purposes of this study, a de-
identified database of pre-existing records from unique patients with esophageal biopsies
was generated.
Study population
Cases comprised all patients with esophageal eosinophilia on esophageal biopsy. By
definition, cases had histology demonstrating a prominent epithelial infiltration of
eosinophils, as described in standardized coding by pathologists (either as “active
esophagitis with increased intraepithelial eosinophils” or as an “eosinophilic esophagitis
pattern or injury”).20 Cases were termed “any esophageal eosinophilia”.
Controls were all patients with normal esophageal biopsies (unremarkable squamous
mucosa). By definition, controls had no evidence of esophageal eosinophilia or other
pathologic processes such as non-eosinophilic inflammation of any type, epithelial erosion
or ulceration, infection with viral or fungal pathogens, or cellular metaplasia, dysplasia, or
neoplasia.
The main exposure was the presence of active H. pylori infection on gastric biopsy. A
diagnosis of Helicobacter gastritis was made when H. pylori organisms were detected in a
gastric biopsy using an H. pylori-specific immunohistochemical stain (anti-H. pylori rabbit
polyclonal antibody; Cell-Marque, Rocklin, CA), and there was concomitant chronic and/or
active inflammation (with or without intestinal metaplasia) in the gastric mucosa, per the
updated Sydney classification.21, 22
Other histologic characteristics of interest included a quantification of the severity of
esophageal eosinophilic density in ranges of eosinophils per high-power (400x) field (eos/
hpf; area per hpf = 0.237 mm2), the presence of eosinophilic microabscesses (defined as
clusters of ≥ 4 contiguous eosinophils),23 the presence of reflux esophagitis (defined as a
mixed active/chronic inflammatory pattern with squamous papillomatosis and basal
hyperplasia), the presence of intestinal metaplasia (Barrett’s esophagus), and the presence of
infectious esophagitis (defined as histopathologic evidence of either candida, herpes simplex
virus, or cytomegalovirus on esophageal biopsy specimens).
Clinical characteristics of interest included upper gastrointestinal symptoms or conditions as
derived from the indication for endoscopy (ie: suspected EoE; dysphagia symptoms; reflux
symptoms or GERD (defined as a report of heartburn, regurgitation, or reflux); screening or
follow-up of a known diagnosis of Barrett’s esophagus; abdominal pain or dyspepsia; chest
pain; nausea or vomiting; and weight loss or failure to thrive).
Statistical Analysis
Means and standard deviations were reported for continuous variables. Proportions were
reported for categorical data. Bivariate analyses were performed using Student’s t-test for
continuous characteristics or Pearson’s chi-square for categorical characteristics. Unadjusted
odds ratios (ORs) were calculated to assess the association between case-control status and
the presence of H. pylori. To adjust for potential confounders noted on bivariate analysis,
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multivariate analyses were performed using logistic regression. A backwards elimination
strategy was used to reduce the model, retaining those covariates whose removal would have
caused a change in estimate of greater than 10% in the estimate of the effect of the
association between H. pylori and esophageal eosinophilia. The initial model contained age,
sex, dysphagia, abdominal pain, and reflux symptoms as defined above. Age was retained in
the final model. Analyses were performed with STATA (version 11.0, College Station,
Texas).
Sensitivity Analyses
We planned for several a priori sensitivity analyses. First, a dose-response analysis was
performed for the association between H. pylori and increasing levels of esophageal
eosinophilia on biopsy (nested categories of ≥ 15, ≥ 45, ≥75, and ≥ 90 eos/hpf), and a p for
trend was calculated. These categories were chosen empirically based on the available data
distributions. In addition, there were some reports where the level of esophageal
eosinophilia was included in the text of the pathology report but there was not an associated
standardized pathology code. These cases were included in the “≥ 15 eos/hpf” category but
were not previously included in the “any esophageal eosinophilia” case definition as
described above.
A second analysis was performed to approximate an increasing clinical likelihood of EoE.
We began with patients who were unlikely to have EoE who had pathology consistent with
reflux esophagitis. We then applied progressively restrictive limits on the presence of
esophageal eosinophilia. First, we defined a group termed “histologic eosinophilic
esophagitis” comprised of only patients with the standardized pathology interpretation code
of “eosinophilic esophagitis pattern of injury” on esophageal biopsy (as outlined above). We
then restricted this group to those who also had an EGD indication of dysphagia or clinical
suspicion for EoE, and had no histologic evidence of reflux esophagitis or Barrett’s
esophagus. This definition was then further limited to patients who also had eosinophilic
microabscesses in the esophageal epithelium. The last group definition included only
patients with ≥ 90 eos/hpf on esophageal biopsy. We also performed a sub-analysis of the
association between H. pylori and esophageal eosinophilia based on whether the esophageal
biopsy was taken from the proximal or distal esophagus.
The final sensitivity analysis examined the association of “histologic eosinophilic
esophagitis” with different manifestations of H. pylori disease in the stomach, including
chronic active gastritis without H. pylori present, chronic active gastritis with H. pylori
present, and intestinal metaplasia present (with or without H. pylori). The purpose was to
investigate esophageal eosinophilia from the perspective of increasing severity of infection
with H. pylori.24, 25
Results
Patient and biopsy characteristics
Between January 1, 2008 and November 26, 2010, a total of 233,662 unique patients had
esophageal biopsies reviewed (Table 1). The mean age was 55.8 years and 46.1% were
male. The most common indications for endoscopy were GERD (48.6%), abdominal pain
(32.9%) and dysphagia (22.6%). There were 26,982 (11.6%) patients who underwent
endoscopy for suspected EoE on a clinical basis. We identified 165,017 patients with both
esophageal and gastric biopsies. Of these patients, 56,301 (34.1%) had normal esophageal
biopsies, 5,767 (3.5%) had “any esophageal eosinophilia”, and 11,170 (6.8%) had H. pylori
on gastric biopsy (Table 1). While there were many statistical differences given the large
sample size between those who had both esophageal and gastric biopsies and those with
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esophageal biopsies only (Table 1), for the large majority of variables the absolute different
between groups was 1% or less, differences that were not clinically significant.
Of those with both esophageal and gastric biopsies, patients with esophageal eosinophilia
were significantly younger (44 vs 53 years; p < 0.001) and more likely to be male (62% vs
35%; p < 0.001) compared with patients with normal esophageal biopsies (Table 2). They
were also more likely to have an endoscopy indication for suspected EoE or dysphagia and
less likely to have an indication of GERD, abdominal pain or chest pain. Compared to
patients without H. pylori, patients with H. pylori were more likely to have an upper
endoscopy indication for abdominal pain and less likely to have an indication for suspected
EoE, dysphagia, or Barrett’s esophagus (Table 3).
Esophageal eosinophilia and H. pylori
The presence of “any esophageal eosinophilia” was inversely associated with H. pylori (OR:
0.77, 95% CI: 0.69–0.87) (Table 4). Compared to patients with normal esophageal biopsies,
there were reduced odds of H. pylori for patients with ≥ 15 intraepithelial eosinophils per
high-power field (eos/hpf) (OR 0.79; 95% CI 0.70–0.88), ≥ 45 eos/hpf (OR 0.75; 0.61–
0.93), ≥75 eos/hpf (OR 0.72; 0.62–0.83), and ≥ 90 eos/hpf (OR 0.52; 0.31–0.87) (p for trend
< 0.001). These associations held after adjusting for potential confounding factors on
multivariate analysis (Table 4).
Increasing clinical suspicion for EoE was also associated with decreasing odds of H. pylori.
Compared to patients with normal esophageal biopsies, patients with no suspicion of EoE
and reflux esophagitis on biopsy had a borderline inverse association with H. pylori (OR
0.95; 95% CI 0.90–0.99). Patients with “histologic eosinophilic esophagitis” (as defined
above) had reduced odds of H. pylori (OR 0.72; 0.62–0.83). This inverse association was
stronger when limited to those with dysphagia or a clinical suspicion of EoE, no reflux or
Barrett’s esophagus, and eosinophilic microabscesses, (OR 0.63; 0.45–0.87). Again, all
associations held after adjusting for potential confounding factors on multivariate analysis
(Table 4).
There were also differences when evaluating the presence of esophageal eosinophilia in
patients with different manifestations of gastritis and H. pylori. Compared to patients with
normal gastric biopsies, there were reduced odds of “histologic EoE” among patients with
chronic active gastritis but no identifiable H. pylori (OR 0.86; 95% CI 0.64–1.17), patients
with chronic active gastritis and H. pylori present (OR 0.69; 0.59–0.81), and patients with
intestinal metaplasia with or without H. pylori (OR 0.34; 0.23–0.51; p for trend < 0.001).
These associations also held on multivariate analysis (Table 5).
Assessment of biopsy location (proximal vs. distal) as an effect modifier of the association
between H. pylori infection and esophageal eosinophilia demonstrated no significant
difference based on location of the esophageal biopsy (data and full models not shown).
Discussion
Over the past decade, EoE has become a major cause of dysphagia and morbidity and is
commonly encountered in GI practice.1, 4–6, 8–13, 26–28 With such a rapidly evolving
epidemiology, it is plausible that environmental factors play a role. In some cases specific
food allergens or environmental triggers can be identified.29–32 However, the etiology for
the dramatic rise in the incidence of EoE is unknown.
The present study utilized a nationwide pathology database to assess the association between
esophageal eosinophilia and H. pylori, and the results were striking. We found a strong
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inverse association between H. pylori and esophageal eosinophilia, and as the level of
esophageal eosinophilia increased, the odds of H. pylori decreased. With increasingly
stringent case definitions approximating EoE on a clinical basis, the odds of H. pylori also
decreased. In addition, the odds of esophageal eosinophilia were lower with progressively
chronic manifestations of H. pylori disease, as manifest by chronic active gastritis and
intestinal metaplasia.
Despite the common nature of both conditions, the literature describing the relationship
between H. pylori infection and EoE is scant and conflicting. An inverse association of H.
pylori and esophageal eosinophilia has been suggested in one prior report.6 In this secondary
analysis of a population-based study of the prevalence of Barrett’s esophagus, distal
esophageal biopsies were re-reviewed for eosinophil counts. However, there were only 48
patients with esophageal eosinophilia, and 8 with H. pylori. The reported OR in this study
was 0.41, similar to our results. In contrast, a study of eosinophilia throughout all segments
of the GI tract found that patients with H. pylori gastritis had somewhat higher esophageal
eosinophil counts than patients without H. pylori. This study, too, was limited by small
numbers, with only 8 patients with eosinophil counts ≥ 15 eos/hpf.33 To our knowledge,
there have been no prior investigations that also examined esophageal eosinophilia in
relation to the manifestation of H. pylori in the stomach.
There are several possible explanations for our findings. H. pylori has been inversely
associated with conditions such as asthma, allergic rhinitis and atopic dermatitis.16–19 Given
that EoE is believed to be an allergic condition, it makes sense that the same association
exists. The hygiene hypothesis has been used to attribute the recent increase in all allergic
diseases to improved sanitation and reductions in childhood infections, and H. pylori is
typically contracted during childhood.15, 16, 34 From a mechanistic perspective, a Th2-
mediated allergic response is involved in the pathogenesis of EoE,14, 35–37 whereas H. pylori
may drive a Th1 response16 with the regulatory T cell population further modulating the
Th1-Th2 balance. It is intriguing to hypothesize, as has been proposed with other allergic
conditions,16, 38 that early infection with H. pylori might predispose toward a Th1 response
and “protect” from an allergic Th2 response and in turn esophageal eosinophilia. The
observations of the lower odds of H. pylori with increasing esophageal eosinophilia, and
also the low odds of esophageal eosinophilia in subjects with intestinal metaplasia (arguably
a manifestation of chronic infection and potentially a committed Th1 inflammatory response
to H. pylori24), may lend some credence to this hypothesis. We observe that the exact
mechanisms of immune modulation of allergy by chronic infections are largely unknown,
with the model of Th1 versus Th2 responses most likely representing a simplication.39 For
example, recent studies have demonstrated that H. pylori may inhibit the Th17 response and
alter the T regulatory cell balance,39 and H. pylori derived DNA itself may directly inhibit a
Th1 response.40 It remains to be determined whether our findings are attributable to
physiologic reflux of H. pylori or its DNA, a field effect related to systemic immune
alterations, or a different mechanism. In the present study, however, we did not see a clear
trend by biopsy level in the esophagus for the inverse association between H. pylori and
esophageal eosinophilia, arguing against direct exposure of H. pylori or its DNA as a causal
factor for the observed associaton.
Several potential limitations must be considered when interpreting these data. First, because
this study was retrospective and cross-sectional in nature, we were unable to draw
conclusions about causality or mechanisms, only about associations. Second, we had to
restrict our primary outcome to the presence of esophageal eosinophilia, not to EoE itself.
This is because current consensus guidelines hold that EoE is a clinicopathologic condition
and require exclusion of competing causes of esophageal eosinophilia, including GERD,
before the diagnosis of EoE can only be made on a clinical basis.1 However, we recognized
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this possible limitation while designing the study and incorporated sensitivity analyses to
specifically address this issue. The results of these analyses further support our conclusions.
In particular, we observed a stronger inverse association as we assessed progressively more
specific EoE case definitions with higher eosinophil counts, supportive histopathologic
findings like eosinophilic microabscesses, and exclusion of reflux esophagitis and Barrett’s
esophagus.
Issues of possible confounding must also be considered. One possibility is that H. pylori
infection is not causally protective for esophageal eosinophilia but is instead a marker for
general microbial or environmental exposures, or other allergic conditions. If this were the
case, however, it would be unlikely that the odds of esophageal eosinophilia would be lower
with a chronic manifestation of H. pylori such as intestinal metaplasia. It is also possible that
GERD or PPI use could be confounding factors. H. pylori is harder to detect in patients on
concurrent PPI therapy,41 thus if patients had esophageal eosinophilia due to GERD and
were treated with a PPI, it stands to reason that the prevalence of H. pylori would be lower.
In addition, H. pylori can reduce gastric acid section which may also have an impact on
esophageal eosinophilia. However, when we controlled for reflux symptoms on
multivariable analysis there was no change in the observed association, and when patients
with reflux esophagitis or histologically-confirmed Barrett’s esophagus were excluded in
our more stringent case definition, the odds ratio for H. pylori was farther from the null, the
opposite of what would be expected if GERD were a confounder. The careful pathologic
characterization of a large number of esophageal biopsies using a standardized system of
interpretation, in combination with the sensitivity analyses performed for this study, lend
validity to our results. This is by far the largest number of subjects with esophageal
eosinophilia analyzed in the medical literature.
In conclusion, we found that there was a strong inverse association between H. pylori
infection and esophageal eosinophilia in biopsies from a large U.S. national pathology
database with a patient population reflective of general GI practice. The odds of H. pylori
decreased in a dose-response fashion with increasing levels of esophageal eosinophilia and
with increasingly restrictive pathologic definitions of EoE. In addition, the odds of
esophageal eosinophilia decreased with chronic manifestations of H. pylori gastritis and
intestinal metaplasia. While the results of this study cannot speak to causality or biologic
mechanisms, this association may have important implications for future research into
understanding the pathogenesis and evolving epidemiology of EoE.
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Esophageal Biopsies (n = 233,662)
Esophageal and Gastric Biopsies (n =
165,017)
p value**
Mean age ± SD 55.8 ± 16.2 55.1 ± 16.5 < 0.001
 Children (age < 18) (n, %) 3,674 (1.6) 3,469 (2.1) < 0.001
Males (n, %) 107,759 (46.1) 71,488 (43.4) < 0.001
EGD indication (n, %)*
 Suspected EoE 26,982 (11.6) 17,089 (10.4) < 0.001
 Dysphagia 52,787 (22.6) 32,055 (19.4) < 0.001
 GERD/heartburn 113,465 (48.6) 81,843 (49.6) < 0.001
 Barrett’s esophagus (screening or follow-up) 32,257 (13.8) 15,816 (9.6) < 0.001
 Abdominal pain/dyspepsia 76,935 (32.9) 64,720 (39.2) < 0.001
 Chest pain 9,566 (4.1) 6,776 (4.1) 0.64
 Nausea 15,218 (6.5) 12,426 (7.5) < 0.001
 Vomiting 8,850 (3.8) 7,108 (4.3) < 0.001
 Weight loss 6,853 (2.9) 5,311 (3.2) < 0.001
 Failure-to-thrive 96 (0) 92 (0.1) < 0.001
Histologic Characteristics (n, %)
Normal esophageal biopsies 71,948 (30.8) 56,301 (34.1) < 0.001
Any esophageal eosinophilia† 9,995 (4.3) 5,767 (3.5) < 0.001
Histologic eosinophilic esophagitis‡ 7,156 (3.1) 3,959 (2.4) < 0.001
Level of esophageal eosinophilia#
 ≥ 15 eos/hpf 9,981 (4.3) 5,791 (3.5) < 0.001
 ≥ 45 eos/hpf 3,104 (1.3) 1,738 (1.1) < 0.001
 ≥ 75 eos/hpf 1,078 (0.5) 607 (0.4) < 0.001
 ≥ 90 eos/hpf 703 (0.3) 388 (0.2) < 0.001
Eosinophilic microabscesses 2,448 (1.0) 1,330 (0.8) < 0.001
Barrett’s esophagus on histology 30,139 (12.9) 13,933 (8.4) < 0.001
Reflux esophagitis changes on histology 79,536 (34.0) 55,884 (33.9) 0.006
Candidal esophagitis 4,124 (1.8) 2,648 (1.6) < 0.001
CMV esophagitis 16 (0) 9 (0) 0.21
HSV esophagitis 52 (0) 29 (0) 0.02
Helicobacter pylori on gastric biopsy 11,170 (4.8) 11,170 (6.8) < 0.001
*
Patients could have more than one indication for EGD
†
Any esophageal eosinophilia indicates that the examining pathologist noted prominent esophageal eosinophilia, but does not require that the
findings were histologically consistent with EoE in the correct clinical context. This is the main case definition for this study.
‡
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**
p values are for the comparison between patients with both esophageal and gastric biopsies (n = 165,017) and those with esophageal biopsies
without gastric biopsies (n = 68,645), and are based on t-test for continuous variables and Pearson’s chi-square for categorical variables.
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Table 2
Comparison of patients with esophageal eosinophilia and normal esophageal biopsies
Any Esophageal Eosinophilia (n =
5,767)
Normal Esophageal Biopsies (n =
56,301)
p-value*
Mean age (± SD) 43.9 ± 16.9 53.2 ± 17.4 <0.001
Children age < 18 (n, %) 345 (6.0) 2,165 (3.9) <0.001
Male (n, %) 3,592 (62.3) 19,744 (35.1) <0.001
EGD indication (n, %)†
 Suspected EoE 2,110 (36.6) 8,640 (15.4) <0.001
 Dysphagia 2,608 (45.2) 11,525 (20.5) <0.001
 GERD/heartburn 2,535 (44.0) 28,100 (49.9) <0.001
 Barrett’s esophagus (screening or follow-up) 252 (4.4) 3,372 (6.0) <0.001
 Abdominal pain/dyspepsia 1,788 (31.0) 24,014 (42.7) <0.001
 Chest pain 191 (3.3) 3,183 (5.7) <0.001
 Nausea 355 (6.2) 4,578 (8.1) <0.001
 Vomiting 266 (4.6) 2,519 (4.5) 0.629
 Weight loss 99 (1.7) 1,716 (3.1) <0.001
 Failure-to-thrive 8 (0.1) 55 (0.1) 0.351
*
Based on t-test for continuous variables and Pearson’s chi-square for categorical variables for the group of patients with both esophageal and
gastric biopsies
†
Patients could have more than one indication for EGD
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Table 3
Comparison of H. pylori positive and negative patients
HP positive (n = 11,170) HP negative (n = 153,847) p-value*
Mean age (± SD) 56.0 ± 15.4 55.0 ± 16.6 <0.001
Children age < 18 (n, %) 82 (0.73) 3,387 (2.2) <0.001
Male (n, %) 5,105 (45.7) 66,383 (43.2) <0.001
EGD indication (n, %)†
 Suspected EoE 1,070 (9.6) 16,019 (10.4) 0.005
 Dysphagia 1,988 (17.8) 30,067 (19.5) <0.001
 GERD/heartburn 5,347 (47.9) 76,496 (49.7) <0.001
 Barrett’s esophagus (screening or follow-up) 409 (3.7) 15,407 (10.0) <0.001
 Abdominal pain/dyspepsia 5,017 (44.9) 59,703 (38.8) <0.001
 Chest pain 347 (3.1) 6,429 (4.2) <0.001
 Nausea 786 (7.0) 11,640 (7.6) 0.041
 Vomiting 455 (4.1) 6,653 (4.3) 0.207
 Weight loss 531 (4.8) 4,780 (3.1) <0.001
 Failure-to-thrive 4 (0) 88 (0.1) 0.355
*
Based on t-test for continuous variables and Pearson’s chi-square for categorical variables
†
Patients could have more than one indication for EGD
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Table 4
Unadjusted and adjusted odds ratios for the association between H. pylori and histologic esophageal disease
HP positive HP negative ORunadj (95% CI) ORadj (95% CI)*
Main outcome
Normal esophageal biopsies 4,048 52,253 1.00 (ref) 1.00 (ref)
Any esophageal eosinophilia 326 5,441 0.77 (0.69–0.87) 0.82 (0.73–0.92)
By level of eosinophilia†
 ≥ 15 eos/hpf 333‡ 5,458‡ 0.79 (0.70–0.88) 0.83 (0.74–0.93)
 ≥ 45 eos/hpf 96 1,642 0.75 (0.61–0.93) 0.81 (0.66–1.00)
 ≥ 75 eos/hpf 32 575 0.72 (0.50–1.03) 0.77 (0.54–1.10)
 ≥ 90 eos/hpf 15 373 0.52 (0.31–0.87) 0.56 (0.33–0.97)
By “EoE” certainty†
Reflux esophagitis on biopsy 3,798 52,086 0.94 (0.90–0.99) 0.94 (0.89–0.98)
Any esophageal eosinophilia 326 5,441 0.77 (0.69–0.87) 0.82 (0.73–0.92)
Histologic eosinophilic esophagitis 208 3,751 0.72 (0.62–0.83) 0.77 (0.66–0.89)
Histologic eosinophilic esophagitis, with dysphagia or clinical
suspicion for EoE, and no reflux or Barrett’s esophagus
121 2,246 0.70 (0.58–0.84) 0.74 (0.61–0.89)
Histologic eosinophilic esophagitis, with dysphagia or clinical
suspicion for EoE, and no reflux or Barrett’s esophagus, and
esophageal eosinophilic microabscess
38 778 0.63 (0.45–0.87) 0.68 (0.49–0.94)
≥ 90 eos/hpf 15 373 0.52 (0.31–0.87) 0.56 (0.33–0.97)
*
Adjusted for age on multivariate analysis with logistic regression
†
p for trend < 0.001
‡
There are some reports where the level of esophageal eosinophilia was included in the text of the pathology report but there was not an associated
standardized pathology code. These cases were included in the “≥ 15 eos/hpf” category but could not be included in the “any esophageal
eosinophilia” case definition.
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Table 5





No esophageal eosinophilia ORunadj (95% CI) ORadj (95% CI)*
Normal gastric biopsies 841 30,481 1.00 (ref) 1.00 (ref)
Chronic active gastritis without HP 44 1,851 0.86 (0.64–1.17) 1.01 (0.74–1.38)
Chronic active gastritis with HP 193 10,131 0.69 (0.59–0.81) 0.79 (0.68–0.93)
Intestinal metaplasia† 25 2,641 0.34 (0.23–0.51)‡ 0.59 (0.40–0.89)‡
*
Adjusted for age on multivariate analysis with logistic regression
†
Includes patients with HP (n = 7) and without HP (n = 18); there was no difference in the OR in these two subgroups.
‡
p for trend < 0.001 for both the unadjusted and adjusted ORs
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